JP2010503630A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010503630A5 JP2010503630A5 JP2009527748A JP2009527748A JP2010503630A5 JP 2010503630 A5 JP2010503630 A5 JP 2010503630A5 JP 2009527748 A JP2009527748 A JP 2009527748A JP 2009527748 A JP2009527748 A JP 2009527748A JP 2010503630 A5 JP2010503630 A5 JP 2010503630A5
- Authority
- JP
- Japan
- Prior art keywords
- hmgb1
- box
- polymer
- amino acid
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000642 polymer Polymers 0.000 claims 24
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 claims 17
- 102000055207 HMGB1 Human genes 0.000 claims 17
- 108700010013 HMGB1 Proteins 0.000 claims 17
- 101150021904 HMGB1 gene Proteins 0.000 claims 17
- 150000001413 amino acids Chemical group 0.000 claims 15
- 229920001184 polypeptide Polymers 0.000 claims 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 239000012634 fragment Substances 0.000 claims 10
- 235000001014 amino acid Nutrition 0.000 claims 8
- 239000002131 composite material Substances 0.000 claims 6
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 102000053637 human HMGB1 Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 230000007170 pathology Effects 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 102000002689 Toll-like receptor Human genes 0.000 claims 3
- 108020000411 Toll-like receptor Proteins 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 230000000975 bioactive effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims 2
- 229920000120 polyethyl acrylate Polymers 0.000 claims 2
- 239000004626 polylactic acid Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 241000256186 Anopheles <genus> Species 0.000 claims 1
- 241000256182 Anopheles gambiae Species 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 208000012657 Atopic disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 108700012434 CCL3 Proteins 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 102000000013 Chemokine CCL3 Human genes 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 208000027205 Congenital disease Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000003814 Interleukin-10 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 102000003816 Interleukin-13 Human genes 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 102000003810 Interleukin-18 Human genes 0.000 claims 1
- 108090000171 Interleukin-18 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 claims 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000007792 addition Methods 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 239000000430 cytokine receptor antagonist Substances 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 230000000642 iatrogenic effect Effects 0.000 claims 1
- 208000036260 idiopathic disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims 1
- 229920001308 poly(aminoacid) Polymers 0.000 claims 1
- 229920002401 polyacrylamide Polymers 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 239000004584 polyacrylic acid Substances 0.000 claims 1
- 229920001515 polyalkylene glycol Polymers 0.000 claims 1
- 239000004633 polyglycolic acid Substances 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06019362 | 2006-09-15 | ||
| US90477607P | 2007-03-05 | 2007-03-05 | |
| PCT/EP2007/008029 WO2008031612A1 (en) | 2006-09-15 | 2007-09-14 | Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015139496A Division JP2015193646A (ja) | 2006-09-15 | 2015-07-13 | ＨＭＢＧ１のＢｏｘ−ＡおよびＨＭＧＢ１のＢｏｘ−Ａ変異体のポリマー複合体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010503630A JP2010503630A (ja) | 2010-02-04 |
| JP2010503630A5 true JP2010503630A5 (enExample) | 2010-10-21 |
Family
ID=38969804
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009527748A Pending JP2010503630A (ja) | 2006-09-15 | 2007-09-14 | ＨＭＧＢ１のＢｏｘ−ＡおよびＨＭＧＢ１のＢｏｘ−Ａ変異体のポリマー複合体 |
| JP2015139496A Pending JP2015193646A (ja) | 2006-09-15 | 2015-07-13 | ＨＭＢＧ１のＢｏｘ−ＡおよびＨＭＧＢ１のＢｏｘ−Ａ変異体のポリマー複合体 |
| JP2017113232A Pending JP2017200930A (ja) | 2006-09-15 | 2017-06-08 | ＨＭＢＧ１のＢｏｘ−ＡおよびＨＭＧＢ１のＢｏｘ−Ａ変異体のポリマー複合体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015139496A Pending JP2015193646A (ja) | 2006-09-15 | 2015-07-13 | ＨＭＢＧ１のＢｏｘ−ＡおよびＨＭＧＢ１のＢｏｘ−Ａ変異体のポリマー複合体 |
| JP2017113232A Pending JP2017200930A (ja) | 2006-09-15 | 2017-06-08 | ＨＭＢＧ１のＢｏｘ−ＡおよびＨＭＧＢ１のＢｏｘ−Ａ変異体のポリマー複合体 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US8546547B2 (enExample) |
| EP (1) | EP2068935B8 (enExample) |
| JP (3) | JP2010503630A (enExample) |
| AU (1) | AU2007296843C1 (enExample) |
| CA (1) | CA2663300C (enExample) |
| HR (1) | HRP20110487T1 (enExample) |
| IL (1) | IL197441A (enExample) |
| MX (1) | MX2009002820A (enExample) |
| PL (1) | PL2068935T3 (enExample) |
| WO (1) | WO2008031612A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110017371A (ko) | 2008-04-30 | 2011-02-21 | 가부시키가이샤 제노믹스 | 생체내 기능적 세포의 고효율 채취법 |
| US20120165244A1 (en) * | 2008-10-30 | 2012-06-28 | Hua-Lin Wu | Methods for binding lewis y antigen |
| CN101691580B (zh) * | 2009-09-28 | 2012-02-15 | 中国人民解放军第三军医大学 | 人HMGB1 A box和酸性尾端的新型融合蛋白及其应用 |
| JP5467313B2 (ja) * | 2009-09-28 | 2014-04-09 | 国立大学法人 岡山大学 | アテローム動脈硬化抑制剤 |
| KR20120135190A (ko) | 2009-10-28 | 2012-12-12 | 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 | 골수 간엽계 및/또는 다능성 줄기세포의 혈중 동원(動員)에 의한 조직 재생 촉진제 |
| US20110123483A1 (en) * | 2009-11-23 | 2011-05-26 | Deutsches Krebsforschungszentrum | Hmgb1 for cancer treatment |
| US8981025B2 (en) | 2011-02-10 | 2015-03-17 | Corning Incorporated | Polymerizable catonic peptide monomers and polymers |
| KR102113809B1 (ko) | 2011-04-26 | 2020-05-21 | 가부시키가이샤 스템림 | 조직 재생을 유도하기 위한 펩티드 및 그의 이용 |
| ES2661500T3 (es) | 2012-07-26 | 2018-04-02 | Ospedale San Raffaele S.R.L. | Variantes de HMGB1 y sus usos |
| GB201508337D0 (en) | 2015-05-15 | 2015-06-24 | Hmgbiotech S R L | Novel peptides |
| JP7107839B2 (ja) | 2015-12-11 | 2022-07-27 | ルプレヒト－カールス－ウニベルジテート ハイデルベルク | Ｐｋｍ２モジュレーター及びｈｍｇｂ１の組合せ製剤 |
| PL3556378T3 (pl) | 2017-01-27 | 2025-06-09 | StemRIM Inc. | Środek do leczenia kardiomiopatii, starego zawału mięśnia sercowego i przewlekłej niewydolności serca |
| US11298403B2 (en) | 2017-12-01 | 2022-04-12 | StemRIM Inc. | Therapeutic agent for inflammatory bowel disease |
| CN118460462A (zh) | 2017-12-01 | 2024-08-09 | 斯特姆里姆有限公司 | 外胚层间充质干细胞及其产生方法 |
| WO2019156137A1 (ja) | 2018-02-08 | 2019-08-15 | 株式会社ステムリム | 乾癬の治療薬 |
| WO2020072993A1 (en) * | 2018-10-05 | 2020-04-09 | Research Institute At Nationwide Children's Hospital | Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application |
| US12304933B2 (en) | 2018-10-05 | 2025-05-20 | StemRIM Inc. | Disease treatment drug based on mesenchymal-stem-cell mobilization |
| JP7448126B2 (ja) * | 2018-10-25 | 2024-03-12 | 国立大学法人大阪大学 | 軟骨疾患の治療薬 |
| US11684653B2 (en) * | 2019-03-06 | 2023-06-27 | The Cleveland Clinic Foundation | Compositions and method for reducing virulence of microorganisms |
| CA3164781A1 (en) | 2019-12-18 | 2021-06-24 | F. Hoffmann-La Roche Ag | Methods of sequencing by synthesis using a consecutive labeling scheme |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3676670D1 (de) * | 1985-06-26 | 1991-02-07 | Cetus Corp | Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung. |
| DK1656952T3 (da) * | 1998-10-16 | 2014-01-20 | Biogen Idec Inc | Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf |
| TR200301208T2 (tr) | 2001-02-01 | 2005-05-23 | Biogen, Inc. | Nublastin polimer eşlenikleri ve bunları kullanma yöntemleri. |
| US7754217B2 (en) | 2001-03-16 | 2010-07-13 | Bio3 Research Srl | HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
| BR0209689A (pt) * | 2001-05-15 | 2006-02-07 | Long Island Jewish Res Inst | Uso de fragmento de hmg como agente anti-inflamatório |
| WO2004046345A2 (en) | 2002-11-20 | 2004-06-03 | Critical Therapeutics, Inc. | Use of hmgb fragments as anti-inflammatory agents |
| MXPA05006688A (es) | 2002-12-19 | 2006-02-22 | Nektar Therapeutics Al Corp | Conjugados de polimero con una variante de cianovirina. |
| TW200510454A (en) | 2003-04-15 | 2005-03-16 | Smithkline Beecham Corp | Conjugates comprising human IL-18 and substitution mutants thereof |
| AU2005319099B2 (en) | 2004-02-02 | 2010-09-16 | Ambrx, Inc. | Modified human growth hormone |
| EP1814576A2 (en) * | 2004-07-20 | 2007-08-08 | Critical Therapeutics, Inc. | Combination therapies of hmgb and complement inhibitors against inflammation |
| AU2005279308B2 (en) * | 2004-09-03 | 2012-05-03 | Creabilis Therapeutics S.R.L. | Protease resistant human and non-human HMGB1 Box-A mutants and their therapeutic/diagnostic use |
| HRP20140218T4 (hr) | 2005-08-25 | 2017-06-16 | Creabilis Therapeutics S.P.A. | Polimerni konjugati k-252a i njihovi derivati |
-
2007
- 2007-09-14 HR HR20110487T patent/HRP20110487T1/hr unknown
- 2007-09-14 US US12/441,478 patent/US8546547B2/en not_active Expired - Fee Related
- 2007-09-14 AU AU2007296843A patent/AU2007296843C1/en not_active Ceased
- 2007-09-14 WO PCT/EP2007/008029 patent/WO2008031612A1/en not_active Ceased
- 2007-09-14 JP JP2009527748A patent/JP2010503630A/ja active Pending
- 2007-09-14 CA CA2663300A patent/CA2663300C/en not_active Expired - Fee Related
- 2007-09-14 PL PL07818168T patent/PL2068935T3/pl unknown
- 2007-09-14 MX MX2009002820A patent/MX2009002820A/es active IP Right Grant
- 2007-09-14 EP EP07818168A patent/EP2068935B8/en not_active Revoked
-
2009
- 2009-03-05 IL IL197441A patent/IL197441A/en active IP Right Grant
-
2012
- 2012-12-27 US US13/728,455 patent/US9707298B2/en not_active Expired - Fee Related
-
2015
- 2015-07-13 JP JP2015139496A patent/JP2015193646A/ja active Pending
-
2017
- 2017-04-28 US US15/581,358 patent/US20170304398A1/en not_active Abandoned
- 2017-06-08 JP JP2017113232A patent/JP2017200930A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110487T1 (hr) | Polimerni konjugati hmgb1 box-a i varijanti hmgb1 box-a | |
| JP6995933B2 (ja) | インターロイキン２３受容体の経口ペプチド阻害剤および炎症性腸疾患を処置するためのそれらの使用 | |
| CA2446942C (en) | Use of il-18 inhibitors for the treatment or prevention of sepsis | |
| JP2008511300A5 (enExample) | ||
| RU2009114149A (ru) | Конъюгаты с полимером а-бокса hmgb1 и вариантов а-бокса hmgb1 | |
| JP2009534423A (ja) | Ｇｌｐ−１化合物 | |
| CN102203118B (zh) | 白介素-15活性的肽拮抗剂 | |
| Poosti et al. | Targeted inhibition of renal Rho kinase reduces macrophage infiltration and lymphangiogenesis in acute renal allograft rejection | |
| RU2018127330A (ru) | Композиция, включающая агонист рецептора glp-1 и агонист глюкагонового рецептора, и ее применение | |
| CA2797247C (en) | Methods and uses of tie2 binding and/or activating agents | |
| KR20220021895A (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 혈압 강하용 약학 조성물 | |
| JP2009533347A (ja) | 抗ＴＮＦα抗体の複合体 | |
| CN108025040A (zh) | 使用白介素-10治疗疾病和病症的方法 | |
| CN111788217B (zh) | 白介素-15活性的拮抗剂肽 | |
| US20110229433A1 (en) | Use of modified interleukin-8 proteins for treating reperfusion injury or transplant rejection | |
| AU2002309887B2 (en) | Use of IL-18 inhibitors for the treatment or prevention of sepsis | |
| Zhang et al. | Cationic Microparticles Inhibit Local Sterile Inflammation in Tissue Injuries | |
| KR20230149258A (ko) | 장질환의 예방 또는 치료를 위한 GLP-2와, 인슐린 분비 펩타이드, TNFα 억제제, 또는 이 둘 모두의 병용 요법 | |
| Dinarello | Role of IL-18 in inflammatory diseases | |
| AU2002309887A1 (en) | Use of IL-18 inhibitors for the treatment or prevention of sepsis | |
| HK1134779B (en) | Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1 | |
| Menna et al. | 235 A nonapeptide epitope shared betwen Par o 1, the major pollen allergen of parietaria and rotavirus VP4 protein | |
| Roebuck et al. | 234 Chemokine induction by TNFα, hydrogen peroxide, and respiratory synctial birus involves differential activation of the transcription factors AP-1 and NF-κB | |
| CN108430583A (zh) | 使用白介素-10治疗疾病和病症的方法 | |
| WO2012052995A2 (en) | Treatment and prevention of hepatocellular carcinoma with chemokine receptor modulators |